Pharmacy News Article

By a News Reporter-Staff News Editor at Marketing Weekly News Breckenridge Pharmaceutical, Inc. announced that Breckenridge and Alembic Pharmaceuticals Limited have settled their Paragraph IV patent litigation with Novartis concerning Rivastigmine Tartrate Capsules, a generic version of Exelon by Novartis, and that the U.S. Food and Drug Administration (FDA) approved their Abbreviated New Drug Application (ANDA). The companies will launch immediately. Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the ANDA, which will be marketed exclusively by Breckenridge. Under the terms of the settlement agreement, Novartis has granted Breckenridge and Alembic a license to market a generic version of Exelon before the expiration of U.S. Patent No. 5,602,176, on February 11, 2014.

Rivastigmine Tartrate Capsules is a prescription medicine that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type, and for the treatment of mild to moderate dementia associated with Parkinson's disease. The current generic market is approximately $46M, based on industry sales data. The product will be available in 4 strengths: 1.5mg, 3mg, 4.5mg & 6mg.

Keywords for this news article include: Breckenridge Pharmaceutical Inc., Pharmaceutical Company, Dementia, Generics, Tartrates, Novartis AG, Sugar Acids, Legal Issues, Brain Diseases, Dicarboxylic Acids, Central Nervous System Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC